Bank Of Montreal Innoviva, Inc. Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Innoviva, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 15,907 shares of INVA stock, worth $282,985. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,907

Previous 19,348 17.78%

Holding current value

$282,985

Previous $317,000 3.15%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$16.33 - $20.04 $56,191 - $68,957	-3,441 Reduced 17.78%	15,907 $307,000
Q2 2024 Aug 14, 2024	SELL	$14.4 - $16.4 $2,260 - $2,574	-157 Reduced 0.8%	19,348 $317,000
Q1 2024 May 13, 2024	BUY	$14.56 - $16.78 $41,204 - $47,487	2,830 Added 16.97%	19,505 $297,000
Q4 2023 Feb 08, 2024	BUY	$12.32 - $16.27 $66,330 - $87,597	5,384 Added 47.68%	16,675 $267,000
Q3 2023 Nov 01, 2023	SELL	$12.37 - $13.89 $6,716 - $7,542	-543 Reduced 4.59%	11,291 $146,000
Q2 2023 Aug 02, 2023	BUY	$11.39 - $13.72 $64,831 - $78,094	5,692 Added 92.67%	11,834 $150,000
Q1 2023 Jun 13, 2024	SELL	$10.73 - $13.6 $87,417 - $110,799	-8,147 Reduced 41.77%	11,358 $127,000
Q4 2022 Feb 01, 2023	BUY	$11.8 - $13.78 $72,475 - $84,636	6,142 New	6,142 $81,000
Q2 2022 Aug 11, 2022	SELL	$14.32 - $19.88 $265,235 - $368,217	-18,522 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$15.39 - $20.25 $26,086 - $34,323	1,695 Added 10.07%	18,522 $356,000
Q4 2021 Feb 11, 2022	SELL	$15.91 - $18.72 $69,335 - $81,581	-4,358 Reduced 20.57%	16,827 $298,000
Q3 2021 Nov 12, 2021	SELL	$13.06 - $17.24 $1,932 - $2,551	-148 Reduced 0.69%	21,185 $366,000
Q2 2021 Aug 12, 2021	BUY	$11.45 - $13.96 $244,262 - $297,808	21,333 New	21,333 $284,000

Others Institutions Holding INVA

# of Institutions

227

Shares Held

78.9M

Call Options Held

37.6K

Put Options Held

300

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account